Universität zu Köln

Lawless, Sarah, Sbianchi, Giulia, Morris, Curly, Iacobelli, Simona, Bosman, Paul, Blaise, Didier, Remenyi, Peter, Byrne, J. L., Mayer, Jiri, Apperley, Jane, Lund, Johan, Kobbe, Guido, Schaap, Nicolaas, Isaksson, Cecilia, Lenhoff, Stig, Basak, Grzegorz, Touzeau, Cyrille, Wilson, Keith M. O., Gonzalez Muniz, Soledad, Scheid, Christof, Browne, Paul, Anagnostopoulos, Achilles, Rambaldi, Alessandro, Jantunen, Esa, Kroeger, Nicolaus, Schoenland, Stefan, Yakoub-Agha, Ibrahim and Garderet, Laurent (2021). IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study. Clin. Lymphoma Myeloma Leuk., 21 (10). S. 686 - 694. DALLAS: CIG MEDIA GROUP, LP. ISSN 2152-2669

Full text not available from this repository.

Abstract

The rare myelomas, immunoglobulin (Ig)D, IgM, and non-secretory, have been associated with poorer outcomes following treatment than the common myelomas (IgG, IgA, and light-chain only). We show that even with novel therapies, augmented with autologous transplantation, this remains true for IgD myeloma. In contrast, IgM and non-secretory myelomas have a prognosis similar to the usual myelomas. Background: The Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study has provided an opportunity to evaluate the real-world outcomes of patients with myeloma. The aim of this study was to compare the outcome according to the different subtypes of myeloma using CALM data. Patients: This study compared overall survival (OS), progression-free survival (PFS), and complete remission (CR) and the impact of novel versus non-novel drug containing induction regimens prior to autologous hematopoietic cell transplantation (HCT) of 2802 patients with usual and rare myelomas. Results: Our data suggest that IgM and non-secretory myeloma have superior PFS and OS compared with IgD myeloma and outcomes comparable to those for usual myeloma. Patients who received novel agent induction had higher rates of CR prior to transplant. Non-novel induction regimens were associated with inferior PFS but no difference in OS. Although not the primary focus of this study, we show that poor mobilization status is associated with reduced PFS and OS, but these differences disappear in multivariate analysis suggesting that poor mobilization status is a surrogate for other indicators of poor prognosis. Conclusion: We confirm that IgD myeloma is associated with the worst prognosis and inferior outcomes compared with the other isotypes. (C) 2021 Elsevier Inc. All rights reserved.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Lawless, Sarah UNSPECIFIED UNSPECIFIED UNSPECIFIED Sbianchi, Giulia UNSPECIFIED UNSPECIFIED UNSPECIFIED Morris, Curly UNSPECIFIED UNSPECIFIED UNSPECIFIED Iacobelli, Simona UNSPECIFIED UNSPECIFIED UNSPECIFIED Bosman, Paul UNSPECIFIED UNSPECIFIED UNSPECIFIED Blaise, Didier UNSPECIFIED UNSPECIFIED UNSPECIFIED Remenyi, Peter UNSPECIFIED UNSPECIFIED UNSPECIFIED Byrne, J. L. UNSPECIFIED UNSPECIFIED UNSPECIFIED Mayer, Jiri UNSPECIFIED UNSPECIFIED UNSPECIFIED Apperley, Jane UNSPECIFIED UNSPECIFIED UNSPECIFIED Lund, Johan UNSPECIFIED UNSPECIFIED UNSPECIFIED Kobbe, Guido UNSPECIFIED UNSPECIFIED UNSPECIFIED Schaap, Nicolaas UNSPECIFIED UNSPECIFIED UNSPECIFIED Isaksson, Cecilia UNSPECIFIED UNSPECIFIED UNSPECIFIED Lenhoff, Stig UNSPECIFIED UNSPECIFIED UNSPECIFIED Basak, Grzegorz UNSPECIFIED UNSPECIFIED UNSPECIFIED Touzeau, Cyrille UNSPECIFIED UNSPECIFIED UNSPECIFIED Wilson, Keith M. O. UNSPECIFIED UNSPECIFIED UNSPECIFIED Gonzalez Muniz, Soledad UNSPECIFIED UNSPECIFIED UNSPECIFIED Scheid, Christof UNSPECIFIED UNSPECIFIED UNSPECIFIED Browne, Paul UNSPECIFIED UNSPECIFIED UNSPECIFIED Anagnostopoulos, Achilles UNSPECIFIED UNSPECIFIED UNSPECIFIED Rambaldi, Alessandro UNSPECIFIED UNSPECIFIED UNSPECIFIED Jantunen, Esa UNSPECIFIED UNSPECIFIED UNSPECIFIED Kroeger, Nicolaus UNSPECIFIED UNSPECIFIED UNSPECIFIED Schoenland, Stefan UNSPECIFIED UNSPECIFIED UNSPECIFIED Yakoub-Agha, Ibrahim UNSPECIFIED UNSPECIFIED UNSPECIFIED Garderet, Laurent UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-606869
DOI:	10.1016/j.clml.2021.05.012
Journal or Publication Title:	Clin. Lymphoma Myeloma Leuk.
Volume:	21
Number:	10
Page Range:	S. 686 - 694
Date:	2021
Publisher:	CIG MEDIA GROUP, LP
Place of Publication:	DALLAS
ISSN:	2152-2669
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language MOBILIZATION; EFFICACY; AGENTS Multiple languages Oncology; Hematology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/60686